1258402-42-4

Basic information

• Product Name: Imidazo[1,2-a]pyridine, 6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2-(trifluoromethyl)-
• CAS NO: 1258402-42-4
• Molecular Formula: C14H16BF3N2O2
• Molecular Weight: 312.09500
• Mol File: 1258402-42-4.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: Imidazo[1,2-a]pyridine, 6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2-(trifluoromethyl)-(CAS DataBase Reference)
• NIST Chemistry Reference: Imidazo[1,2-a]pyridine, 6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2-(trifluoromethyl)-(1258402-42-4)
• EPA Substance Registry System: Imidazo[1,2-a]pyridine, 6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2-(trifluoromethyl)-(1258402-42-4)

Safety Data

• Hazardous Substances Data: 1258402-42-4(Hazardous Substances Data)

Upstream product

• 150780-40-8 6-bromo-2-trifluoromethylimidazo[1,2-a]pyridine 
• 73183-34-3 bis(pinacol)diborane 

Relevant articles and documents

SUBSTITUTED QUINOLINES AND THEIR USE AS MEDICAMENTS

The invention relates to new substituted quinolines of formula (1) wherein R1 is a linear or branched C1-6-alkyl, wherein R1 may optionally be substituted by R3 which is selected from the group consisting of a three-, four-, five-, six- or seven-membered cycloalkl; a five-, six- or seven-membered, saturated heterocycle comprising one, two or three heteroatoms each independently selected from the group consisting of N, S and O; and a five- or six-membered heteroaryl comprising one, two or three heteroatoms each independently selected from the group consisting of N, S and O; wherein R3 may optionally be substituted further substituted as defined in claim 1 and wherein R2 is selected from the group consisting of halogen, phenyl, a five- or six-membered monocyclic heteroaryl comprising one, two or three heteroatoms each independently selected from the group consisting of N, S and O; a bicyclic, nine-, ten- or eleven-membered, either aromatic or non-aromatic, but not fully saturated heterocycle comprising one, two, three or four heteroatoms each independently selected from the group consisting of N, S and O; wherein R2 may optionally be further substituted as defined in claim 1, and their use in the preparation of medicaments for the treatment of disease such as asthma, COPD, allergic rhinitis, allergic dermatitis and rheumatoid arthritis.

NOVEL FUSED CYCLIC COMPOUND AND USE THEREOF

A compound represented by the formula (I): wherein each symbol is as defined in the specification, and a salt thereof have a GPR40 receptor activation action and is useful as an insulin secretagogue or a prophylactic or therapeutic drug for diabetes and the like.